Tatva Chintan Pharma Chem liquidity ratios

Profitability Growth Credit Liquidity Working capital Dividend yield DuPont CAGR

Per cent unless marked ×

Tap a line for its trend	Last 12Mto Sep 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

9.47×	—	—	—	—	FY22 and earlierEvery year the company has filed comes with Alpha Plus.
1.64×	1.64×	2.76×	3.74×	1.33×
0.72×	0.72×	1.37×	1.82×	0.64×
10.7	5.8	11.4	45.4	27.4
173	136	169	218	77.4

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

TATVA₹1,614.80

Tatva Chintan Pharma Chem Limited

· Chemicals

₹ CrorePeersVISHNU JUBLCPL KIRIINDUS FOSECOIND CHEMPLASTS DDEVPLSTIK GUJALKALI YASHOMcap ₹3,777 Cr

Profitability Growth Credit Liquidity Working Capital Yield Analysis DuPont

Ratios — % unless marked × 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/09/2026
Altman Z-Score (Other Equity as RE)	—	—	—	—	9.47
Current Ratio	1.33	3.74	2.76	1.64	1.64
Quick Ratio	0.64	1.82	1.37	0.72	0.72
Cash, Equiv & ST Investments	27.4	45.4	11.4	5.8	10.7
Working Capital	77.4	218.2	169.2	136.4	173.3

No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.